Classic Hairy Cell Leukemia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

HCL-C MCID: CLS052 MIFTS: 28	Classic Hairy Cell Leukemia (HCL-C) Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Classic Hairy Cell Leukemia

MalaCards integrated aliases for Classic Hairy Cell Leukemia:

Name: Classic Hairy Cell Leukemia ⁵⁸

Leukemic Reticuloendotheliosis ⁵⁸

Hairy Cell Leukemia ⁷¹

Hcl-C ⁵⁸

Characteristics:

Prevelance:

1-9/1000000 (Europe, United States, United Kingdom, Iceland, Denmark) 1-9/100000 (Europe) <1/1000000 (Hong Kong) ⁵⁸

Age Of Onset:

Adult ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Lymphoid leukaemia

Hairy-cell leukaemia

Orphanet: ⁵⁸

Rare haematological diseases

External Ids:

MESH via Orphanet ⁴⁴ D007943

ICD10 via Orphanet ³² C91.4

UMLS via Orphanet ⁷² C0023443

Orphanet ⁵⁸ ORPHA58017

UMLS ⁷¹ C0023443

Sources

Summaries for Classic Hairy Cell Leukemia

Orphanet: ⁵⁸ A rare, slowly progressive, chronic leukemia characterized by presence of abnormal B-lymphocytes (medium sized with abundant irregular pale cytoplasm, hair-like cytoplasmic projections/ruffled cytoplasmic border, a round or bean-shaped nucleus and absent nucleoli) in the blood or bone marrow, spleen and peripheral blood pancytopenia, notable monocytopenia, and marked susceptibility to infection. The characteristic immunophenotype is CD11c+, CD25+, CD103+ and CD123+ with a BRAF mutation in most cases.

MalaCards based summary: Classic Hairy Cell Leukemia, also known as leukemic reticuloendotheliosis, is related to intrapelvic lymph node leukemic reticuloendotheliosis and reticuloendotheliosis, x-linked. An important gene associated with Classic Hairy Cell Leukemia is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase). The drugs Cladribine and 2-chloro-3'-deoxyadenosine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, spleen and bone.

Sources

Related Diseases for Classic Hairy Cell Leukemia

Diseases related to Classic Hairy Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 36)

#	Related Disease	Score
1	intrapelvic lymph node leukemic reticuloendotheliosis	11.5
2	reticuloendotheliosis, x-linked	11.0
3	hairy cell leukemia	10.5
4	aplastic anemia	10.4
5	pancytopenia	10.4
6	leukemia, chronic lymphocytic	10.3
7	hypersplenism	10.2
8	monocytic leukemia	10.2
9	granulocytopenia	10.2
10	leukemia	10.2
11	vasculitis	10.2
12	hypersensitivity vasculitis	10.2
13	bacteremia 2	10.1
14	lymphoproliferative syndrome	10.1
15	hematologic cancer	10.1
16	splenomegaly	10.1
17	neutrophilia, hereditary	10.0
18	down syndrome	10.0
19	mycosis fungoides	10.0
20	human cytomegalovirus infection	10.0
21	qualitative platelet defect	10.0
22	neutropenia	10.0
23	acute leukemia	10.0
24	fungal infectious disease	10.0
25	thrombocytopenia	10.0
26	lymphadenitis	10.0
27	gaucher's disease	10.0
28	blood platelet disease	10.0
29	skin disease	10.0
30	reticulosarcoma	10.0
31	sezary's disease	10.0
32	toxoplasmosis	10.0
33	catastrophic antiphospholipid syndrome	10.0
34	cryopyrin-associated periodic syndrome	10.0
35	mycobacterium kansasii	10.0
36	twin anemia-polycythemia sequence	10.0

Graphical network of the top 20 diseases related to Classic Hairy Cell Leukemia:

Sources

Symptoms & Phenotypes for Classic Hairy Cell Leukemia

Sources

Drugs & Therapeutics for Classic Hairy Cell Leukemia

Drugs for Classic Hairy Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cladribine

Approved, Investigational

Phase 2, Phase 3

4291-63-8

20279

2-chloro-3'-deoxyadenosine

Phase 2, Phase 3

14485373

Alemtuzumab

Approved, Investigational

Phase 2

216503-57-0

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Ondansetron

Approved, Withdrawn

Phase 2

99614-02-5

4595

Levoleucovorin

Approved, Experimental, Investigational

Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Methotrexate

Approved

Phase 2

1959-05-2, 59-05-2

4112 126941

Busulfan

Approved, Investigational

Phase 2

55-98-1

2478

Melphalan

Approved

Phase 2

148-82-3

4053 460612

Mechlorethamine

Approved, Investigational

Phase 2

51-75-2

4033

Vorinostat

Approved, Investigational

Phase 2

149647-78-9

5311

Adenosine

Approved, Investigational

Phase 2

58-61-7

60961

Pentostatin

Approved, Investigational

Phase 2

53910-25-1

439693

Thiotepa

Approved, Investigational

Phase 2

52-24-4

5453

Obinutuzumab

Approved, Investigational

Phase 2

949142-50-1

Prednisone

Approved, Vet_approved

Phase 1, Phase 2

53-03-2

5865

Vemurafenib

Approved

Phase 2

918504-65-1

42611257

Triamcinolone

Approved, Vet_approved

Phase 2

124-94-7

31307

Acalabrutinib

Approved, Investigational

Phase 1, Phase 2

1420477-60-6

71226663 71226662

Pembrolizumab

Approved

Phase 1, Phase 2

1374853-91-4

254741536

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Brentuximab vedotin

Approved, Investigational

Phase 1, Phase 2

914088-09-8

Ipilimumab

Approved

Phase 1, Phase 2

477202-00-9

Iron

Approved

Phase 2

7439-89-6

29936

Deferasirox

Approved, Investigational

Phase 2

201530-41-8

214348 5493381

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 2

59-30-3

6037

D-Phenylalanine

Approved, Experimental, Investigational, Nutraceutical

Phase 2

63-91-2, 673-06-3

6140 71567

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

Phase 2

133585-56-5, 60-18-4, 556-02-5

1153 6057

Veliparib

Investigational

Phase 1, Phase 2

912444-00-9

11960529

Cordycepin

Investigational

Phase 2

73-03-0

248010

Daclizumab

Investigational, Withdrawn

Phase 2

152923-56-3

Neurotransmitter Agents

Phase 2

Antiemetics

Phase 2

Gastrointestinal Agents

Phase 2

Dermatologic Agents

Phase 2

Cyclosporins

Phase 2

Antifungal Agents

Phase 2

Interferon alpha-2

Phase 2

interferons

Phase 2

Interferon-alpha

Phase 2

Bendamustine Hydrochloride

Phase 1, Phase 2

Antipsychotic Agents

Phase 2

Anti-Anxiety Agents

Phase 2

Psychotropic Drugs

Phase 2

Folic Acid Antagonists

Phase 2

Folate

Phase 2

Vitamin B9

Phase 2

Anti-Asthmatic Agents

Phase 2

Vitamin B Complex

Phase 2

Interventional clinical trials:

(show top 50) (show all 95)

#	Name	Status	NCT ID	Phase	Drugs
1	Daily Versus Weekly Administration of 2-Chlorodeoxyadenosine (CDA) in Patients With Hairy Cell Leukemia	Completed	NCT00003746	Phase 3	2-chlorodeoxyadenosine (CDA) daily;2-chlorodeoxyadenosine weekly
2	A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia	Completed	NCT01829711	Phase 3	Moxetumomab pasudotox;IV Bag Protectant for Moxetumomab pasudotox
3	INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation	Completed	NCT00799461	Phase 3
4	Therapy Optimisation for the Treatment of Hairy Cell Leukemia	Recruiting	NCT02131753	Phase 2, Phase 3	Cladribine s.c. injection, HCL treatment
5	Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial	Completed	NCT00040846	Phase 2	fludarabine phosphate;mycophenolate mofetil;cyclosporine
6	A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia	Completed	NCT00001567	Phase 2	Roferon-A
7	Rituximab (IDEC-C2B8, Mabthera) in Patients With Hairy Cell Leukemia Relapsing After Treatment With 2-Chlorodeoxyadenosine (CDA)	Completed	NCT00003757	Phase 2
8	Phase II Trial Of BL22 Immunotoxin In Hairy Cell Leukemia	Completed	NCT00074048	Phase 2	BL22
9	Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies	Completed	NCT01839916	Phase 2
10	A Phase I/II Study of Syk Inhibitor Entospletinib (GS-9973) in Combination With Obinutuzumab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-Cell Malignancies	Completed	NCT03010358	Phase 1, Phase 2	Entospletinib
11	Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-myeloablative Allogeneic Hematopoietic Cell Transplantation With Relapsed or Refractory CD20+ B-Cell Malignancies	Completed	NCT00867529	Phase 2
12	Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells	Completed	NCT00795769	Phase 2	ondansetron
13	A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens	Completed	NCT00489203	Phase 2	beclomethasone dipropionate;placebo;tacrolimus;methotrexate
14	Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial	Completed	NCT00078858	Phase 1, Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
15	A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil	Completed	NCT00089011	Phase 2	fludarabine phosphate;mycophenolate mofetil;tacrolimus
16	Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil	Completed	NCT00006251	Phase 1, Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
17	Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial	Completed	NCT00118352	Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
18	Phase II Study of MK-2206 in Patients With Relapsed Lymphoma	Completed	NCT01258998	Phase 2	Akt inhibitor MK2206
19	A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation	Completed	NCT01529827	Phase 2	fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
20	A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies	Completed	NCT01384513	Phase 2	Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
21	A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation	Completed	NCT01789255	Phase 2	vorinostat;tacrolimus;cyclosporine;methotrexate
22	Study on the Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia	Completed	NCT02157181	Phase 2	2CdA +/- Rituximab
23	A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors	Completed	NCT01326702	Phase 1, Phase 2	Bendamustine Hydrochloride;Veliparib
24	Phase II Study of 2-Chlorodeoxyadenosine (2CDA) Followed by Rituximab in Hairy Cell Leukemia	Recruiting	NCT00412594	Phase 2	Cladribine
25	Phase 2 Trial for Binimetinib for Patients With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant	Recruiting	NCT04322383	Phase 2	binimetinib
26	Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia	Recruiting	NCT01059786	Phase 2	Pentostatin;Rituximab;Bendamustine
27	Randomized Trial of Cladribine (CdA) With Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease	Recruiting	NCT00923013	Phase 2	Cladribine;Rituximab
28	A Single Arm Phase II Pilot Study of Low Dose Vemurafenib Plus Rituximab in the Front-line and Relapsed/Refractory Treatment of Hairy Cell Leukemia	Recruiting	NCT05388123	Phase 2	Low dose vemurafenib plus rituximab
29	A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25)	Recruiting	NCT05537766	Phase 2	Cyclophosphamide;Fludarabine
30	Phase 2 Trial of Encorafenib Plus Binimetinib for Patients With BRAF V600 Mutated Relapsed/Refractory HCL	Recruiting	NCT04324112	Phase 2	binimetinib;Encorafenib
31	A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies	Recruiting	NCT01760655	Phase 2	Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
32	A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia	Active, not recruiting	NCT01841723	Phase 2	Ibrutinib
33	Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas	Active, not recruiting	NCT02213913	Phase 1, Phase 2	lenalidomide;etoposide;prednisone;vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide
34	A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia	Active, not recruiting	NCT03410875	Phase 2	Vemurafenib;Obinutuzumab
35	A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell Leukemia	Active, not recruiting	NCT00321555	Phase 2	Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin
36	A Phase II Study of the BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia	Active, not recruiting	NCT01711632	Phase 2	Vemurafenib
37	A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies	Active, not recruiting	NCT02362035	Phase 1, Phase 2	Acalabrutinib;Pembrolizumab
38	A Phase II Study of Sunitinib Malate in Idiopathic Myelofibrosis	Terminated	NCT00387426	Phase 2	sunitinib malate
39	A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas	Terminated	NCT01805037	Phase 1, Phase 2	brentuximab vedotin
40	Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia	Terminated	NCT00924040	Phase 2	BL22 (CAT-3888)
41	Phase I/II Study of Anti-CTLA-4 Monoclonal Antibody (MDX-010) in B-cell Non-Hodgkin's Lymphoma	Terminated	NCT00089076	Phase 1, Phase 2
42	Deferasirox Treatment and Labile Plasma Iron in Iron Overloaded Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation	Terminated	NCT01159067	Phase 2	deferasirox
43	A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL/SLL/PLL or NHL With Lenalidomide Alone or With Rituximab	Terminated	NCT01419795	Phase 2	lenalidomide
44	A PHASE I/II STUDY OF INTRATUMORAL INJECTION OF IPILIMUMAB IN COMBINATION WITH LOCAL RADIATION IN MELANOMA, NON-HODGKIN LYMPHOMA AND COLORECTAL CARCINOMA	Terminated	NCT01769222	Phase 1, Phase 2
45	A Phase 2 Study to Evaluate the Anti-Tumor Activity of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies	Withdrawn	NCT03739606	Phase 2
46	A Phase I/II Trial of Romidepsin, Rituximab and Lenalidomide (R3) in Relapsed/Refractory B Cell Lymphomas Including Transformed Follicular Lymphoma	Withdrawn	NCT02281279	Phase 1, Phase 2	lenalidomide;romidepsin
47	Hematopoietic Stem Cell Transplantation Using Alternate Donor Umbilical Cord Blood Options	Withdrawn	NCT01652014	Phase 2	cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
48	A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patient With Relapsed or Refractory Hairy Cell Leukemia (HCL)	Unknown status	NCT00462189	Phase 1	Immunotoxin therapy;CAT-8015 Immunotoxin
49	A Phase I Study of Flavopiridol, Fludarabine and Rituximab in Indolent B-cell Lymphoproliferative Disorders and Mantle Cell Lymphoma	Completed	NCT00058227	Phase 1	alvocidib;fludarabine phosphate
50	A Phase I Pharmacokinetic Study of STI571 in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction	Completed	NCT00025415	Phase 1	imatinib mesylate

Search NIH Clinical Center for Classic Hairy Cell Leukemia

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Cladribine

Interferon Alfa-2a

Interferon Alfa-2b

INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED

interferon alfacon-1

Interferon gamma-1b

Interferons

peginterferon alfa-2a

peginterferon alfa-2b

Recombinant interferon beta-1a

Recombinant interferon beta-1b

Sources

Genetic Tests for Classic Hairy Cell Leukemia

Sources

Anatomical Context for Classic Hairy Cell Leukemia

Organs/tissues related to Classic Hairy Cell Leukemia:

MalaCards : Bone Marrow, Spleen, Bone, T Cells, Liver, B Cells, Ovary

Sources

Publications for Classic Hairy Cell Leukemia

Articles related to Classic Hairy Cell Leukemia:

(show top 50) (show all 195)

#	Title	Authors	PMID	Year
1	Protein profiling by reverse phase protein array (RPPA) in classical hairy cell leukemia (HCL) and HCL-variant. ⁶²	Hoff FW...Kornblau SM	36467805	2022
2	Intracavity absorption spectroscopy of HCl isotopes, H2O, CH4, C2H4, and C2H6 in the 3.1-3.4 µm spectral range using a Cr:CdSe laser. ⁶²	Fjodorow P...Yuryshev NN	36298969	2022
3	Synthesis and structure of clozapine N-oxide hemi(hydro-chloride): an infinite hydrogen-bonded poly[n]catenane. ⁶²	van der Peet PL...Williams SJ	36250113	2022
4	[Classic hairy cell leukemia with MAP2K1 mutation: a case report]. ⁶²	Wei C...Zhuang JL	35680604	2022
5	Rotational Mode-Specificity in the Cl + C2H6 → HCl + C2H5 Reaction. ⁶²	Papp D...Czako G	35427141	2022
6	Hairy Cell Leukemia Patients Have a Normal Life Expectancy-A 35-Year Single-Center Experience and Comparison with the General Population. ⁶²	Bohn JP...Wolf D	35267550	2022
7	Treatment of Classic Hairy Cell Leukemia: Targeting Minimal Residual Disease beyond Cladribine. ⁶²	Bohn JP...Dietrich S	35205704	2022
8	Advances in the Treatment of Hairy Cell Leukemia Variant. ⁶²	Tran J...Tallman MS	35178674	2022
9	Vibrational mode-specificity in the dynamics of the Cl + C2H6 → HCl + C2H5 reaction. ⁶²	Papp D...Czako G	34551541	2021
10	Effects of lycopene intake on HDL-cholesterol and triglyceride levels: A systematic review with meta-analysis. ⁶²	Inoue T...Kamioka H	34268742	2021
11	The Biology of Classic Hairy Cell Leukemia. ⁶²	Bohn JP...Wolf D	34360545	2021
12	The Influence of HCl Concentration on the Rate of the Hydrolysis-Condensation Reaction of Phenyltrichlorosilane and the Yield of (Tetrahydroxy)(Tetraphenyl)Cyclotetrasiloxanes, Synthesis of All Its Geometrical Isomers and Thermal Self-Condensation of Them under "Pseudo"-Equilibrium Conditions. ⁶²	Petrova IM...Makarova NN	34299658	2021
13	Classic hairy cell leukemia with an aggressive presentation. ⁶²	Fugere T...Godbole A	34733001	2021
14	Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant. ⁶²	Liu Q...Andritsos LA	33727830	2021
15	A BRAF-Negative Classic Hairy Cell Leukemia Patient with Long-Lasting Complete Remission after Rituximab and Pentostatin ⁶²	Gozzetti A...Bocchia M	32539314	2020
16	Hydrochloric acid corrosion induced bifunctional free-standing NiFe hydroxide nanosheets towards high-performance alkaline seawater splitting. ⁶²	Duan S...Li Q	33094769	2020
17	BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials. ⁶²	Liebers N...Dietrich S	31740808	2020
18	Difference of genomic copy numbers alterations between hairy cell leukemia-variant and classical hairy cell leukemia: a pilot retrospective study in Chinese. ⁶²	Zhang R...Yan X	32132867	2020
19	A Study of the Influence of the HCl Concentration on the Composition and Structure of (Hydroxy)Arylsiloxanes from the Hydrolysis-Condensation Reaction of Aryltrichlorosilanes. ⁶²	Petrova IM...Makarova NN	31752317	2019
20	Non covalent interactions stabilizing the chiral dimer of CH2ClF: a rotational study. ⁶²	Favero LB...Caminati W	30652707	2019
21	Pyrolysis of blend (oil palm biomass and sawdust) biomass using TG-MS. ⁶²	Salema AA...Shang YK	30553084	2019
22	Genome-wide promoter methylation of hairy cell leukemia. ⁶²	Arribas AJ...Forconi F	30723113	2019
23	[Hairy cell leukemia complicated by bone marrow necrosis following cladribine administration]. ⁶²	Terao T...Minami Y	31281144	2019
24	Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib. ⁶²	Shenoi DP...Grever MR	30630817	2019
25	Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience. ⁶²	Angelova EA...Kanagal-Shamanna R	29955146	2018
26	New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes. ⁶²	Maitre E...Troussard X	29989027	2018
27	Survival and detection of Bacillus cereus in the presence of Escherichia coli, Salmonella enteritidis, Staphylococcus aureus, Pseudomonas aeruginosa and Candida albicans after rechallenge in make-up removers. ⁶²	Yossa N...Hammack T	29030872	2018
28	2-(Trimethylsilyl)-λ3 -Phosphinine: Synthesis, Coordination Chemistry, and Reactivity. ⁶²	Habicht MH...Muller C	29068102	2018
29	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. ⁶²	Grever MR...Falini B	27903528	2017
30	What is the association of lipid levels and incident stroke? ⁶²	Glasser SP...Banach M	27400190	2016
31	Intravaginal administration of metformin hydrochloride loaded cationic niosomes amalgamated with thermosensitive gel for the treatment of polycystic ovary syndrome: In vitro and in vivo studies. ⁶²	Saini N...Madan J	27085048	2016
32	"Conformational lock"via unusual intramolecular C-FO[double bond, length as m-dash]C and C-HCl-C parallel dipoles observed in in situ cryocrystallized liquids. ⁶²	Dey D...Chopra D	27149236	2016
33	Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13(7):609-630. ⁶²		27013208	2016
34	Long-term treatment of hairy cell leukemia with interferon-α: still a viable therapeutic option. ⁶²	Bohn JP...Steurer M	27429657	2016
35	BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation. ⁶²	Tsai YT...Lucas DM	26350141	2015
36	Relative stabilities of HCl•H2SO4•HNO3 aggregates in polar stratospheric clouds. ⁶²	Verdes M...Paniagua M	25758341	2015
37	Organotin-oxido cluster-based multiferrocenyl complexes obtained by hydrolysis of ferrocenyl-functionalized organotin chlorides. ⁶²	You Z...Dehnen S	25164865	2014
38	Current therapeutic options in hairy cell leukemia. ⁶²	Mikler E...Mascarenhas J	24971416	2014
39	Diurnal glucose profiles using continuous glucose monitoring to identify the glucose-lowering characteristics of colesevelam HCl (Welchol). ⁶²	Mazze RS...Bergenstal RM	23598534	2013
40	A hairy cell leukaemia variant - a rare case report. ⁶²	Pande P...Kumar U M	23543122	2013
41	[Analysis of clinical and laboratory characteristics and survival with hairy cell leukemia]. ⁶²	Zhang YR...Qiu LG	23328507	2012
42	Anti-hepatitis C virus activity of 3-hydroxy caruilignan C from Swietenia macrophylla stems. ⁶²	Wu SF...Lee JC	22497816	2012
43	Management of hairy cell leukemia variant. ⁶²	Robak T	21599606	2011
44	Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. ⁶²	Robak T	20558005	2011
45	Classical hairy cell leukemia and its variant: a 17-year retrospective survey in Taiwan Chinese. ⁶²	Kao HW...Hung YS	21846972	2011
46	Experimental and computational investigation of C-N bond activation in ruthenium N-heterocyclic carbene complexes. ⁶²	Haller LJ...Whittlesey MK	21128626	2010
47	Primary photodissociation pathways of epichlorohydrin and analysis of the C-C bond fission channels from an O((3)P)+allyl radical intermediate. ⁶²	Fitzpatrick BL...Lin JJ	20831317	2010
48	How I treat hairy cell leukemia. ⁶²	Grever MR	19843881	2010
49	[Effect of hawthorn flavanone on blood-fat and expression of lipogenesis and lipolysis genes of hyperlipidemia model mouse]. ⁶²	Xie W...Liu S	19385191	2009
50	Photocatalytic degradation of dichloromethane by chlorocuprate(II) ions. ⁶²	Doyle KJ...Hoggard PE	18593110	2008